ArticleTranslational lung cancer research2026
CD4
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- IL21 is predominantly produced by a CXCL13 associated CD4Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Synchronous double primary lung adenocarcinoma (sDPLA) is a distinct subtype of lung adenocarcinoma characterized by the co-existence of two independent lesions in the same patient. We conducted the first comprehensive analysis of the immune microenvironment of sDPLA lesions with different degrees of invasiveness to examine immune evolution during early lung adenocarcinoma progression. Methods: In total, 10 sDPLA patients undergoing synchronous surgical resection were enrolled in the study. The minimally invasive adenocarcinoma (MIA) and invasive adenocarcinoma (IAC) lesions were analyzed by next-generation sequencing (NGS) or single-cell RNA sequencing (scRNA-seq), focusing on T/natural killer (NK) cell subsets. The key cell subsets and signaling pathways were identified using Mfuzz clustering, CellChat, and Monocle, and validated by multiplex immunofluorescence and flow cytometry. Results: We identified 11 T/NK cell subsets, among which the CD4 Conclusions: This study found significant immune heterogeneity between sDPLA lesions with different degrees of invasiveness and identified CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.